Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye injections tested to save sight in rare coats disease

NCT ID NCT03940690

Disease control Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether anti-VEGF injections into the eye could help treat Coats disease, a rare condition that causes abnormal blood vessels and fluid buildup in the retina, potentially leading to blindness. The trial included 18 people with early-stage Coats disease who had not received prior eye treatment. Researchers compared the effects of these injections combined with standard laser therapy to see if they could improve disease stage and reduce the need for repeat laser treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

18 people

The number who actually took part.

Started

Oct 2019

Finished

Oct 2023

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 16 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Coats disease confirmed by fundus examination and fluorescein angiography * Stage 2 or 3 at the fundus (Shields classification) * Naive to any eye treatment on the eye affected by Coats disease Exclusion Criteria: * Other ocular pathology on the eye affected by Coats' disease * Bilateral forms of the disease * History of hypersensitivity to bevacizumab * History of hypersensitivity to products of Chinese hamster ovary cells or other recombinant human or humanized antibodies * Allergic reaction in a previous fluorescein retinal angiogram * Pregnancy or breastfeeding * Active or suspected periocular infection * Contraindication to treatments used for general anesthesia and morphine derivatives * Cardiovascular, haemorrhagic and gastrointestinal risks * Premature baby who has not reached the correct age of 37 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coats' disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Coats disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coats' disease Retinal telangiectasis

Contacts and locations

Locations

  • CHU de Bordeaux

    Bourdeaux, 33076, France

  • CHU de Reims

    Reims, France, 51092, France

  • Centre hospitalier René Dubos (Pontoise)

    Cergy-Pontoise, France, 95303, France

  • Clinique Rive Gauche

    Toulouse, France, 31000, France

  • Fondation Ophtalmologique A. de Rothschild

    Paris, France, 75019, France

  • Hôpital Universitaire Necker Enfants Malades, APHP

    Paris, France, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.